Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Revelation Biosciences, Inc. - Common Stock (NQ:REVB)

0.5501 -0.0958 (-14.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revelation Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
REVB Stock Drops 10% After Company Announces Third Reverse Split In A Year ↗
Revelation Biosciences said its 1-for-4 reverse stock split will become effective from January 28, 2026. 
Via Stocktwits
News headline image
American Lithium Minerals (OTC: AMLM) Accelerates Global Expansion Across Gold, Silver, Copper, Critical Minerals, and Rare Earth Elements
Via AB Newswire
What's going on in today's session ↗
Via Chartmill
Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug ↗
Via Stocktwits
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Which stocks are moving on Friday? ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
Thursday's session: top gainers and losers ↗
Via Chartmill
News headline image
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
Via ACCESS Newswire
News headline image
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
Via ACCESS Newswire
News headline image
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESS Newswire
News headline image
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
Via ACCESS Newswire
News headline image
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
REVELATION BIOSCIENCES INC (NASDAQ:REVB) Reports Q3 2025 Loss, Announces Groundbreaking Clinical Data and Improved Cash Runway ↗
Revelation Biosciences posts wider Q3 loss but secures funding, extends cash runway into 2026 following positive Gemini study data. 
Via Chartmill
News headline image
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
Via ACCESS Newswire
News headline image
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
Via ACCESS Newswire
News headline image
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
Via ACCESS Newswire
News headline image
Revelation Biosciences Inc (NASDAQ:REVB) Reports Wider-Than-Expected Q2 2025 Loss, Extends Cash Runway to Year-End ↗
Revelation Biosciences (REVB) reports Q2 2025 earnings with a wider-than-expected loss of $(7.01) per share. Cash runway extends to December 2025, while Phase 1b Gemini trial data for CKD is expected... 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.